Authors must submit manuscripts that are not published, in press, or submitted to other scientific journals, books or other venues that could be considered formal publication (including preprints or future submissions). The correspondence for each article must be carried on only by the corresponding authors, who should provide an institutional and verified email address. Articles without this requirement will not be considered for evaluation or publication.
Original Articles should present novel work that makes a significant impact within the aims and scope of the journal, and which provides an important advancement in the reader’s knowledge or understanding. Supporting data or additional experimental details can be submitted as Supplementary Information. Original Articles may be recommended to be resubmitted as Short Communications at the discretion of the Editors.
All clinical trials submitted to European Review for Medical and Pharmacological Sciences for consideration of publication must be registered. The International Committee of Medical Journal Editors (ICMJE) defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials), are exempt.”
For definitions and further information, please see http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html, found in ICMJE’s Uniform Requirements for Manuscripts Submitted to Biomedical Journals.
Systematic Reviews and Meta-Analyses
Meta-analyses use statistical methods to combine data from multiple and systematically selected studies. These manuscripts should be based on a rigorous methodological and statistical approach described in detail in the methods section applied to a relevant basic or clinical issue. This contribution may also undergo statistical revision.
According to the International Committee of Medical Journal Editors (ICMJE), to conduct a systematic review or meta-analysis, the Authors have to follow the guidelines of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA: http://www.prisma-statement.org/).
To perform a high-quality analysis, the Authors are requested to follow some specific guidelines:
- Authors have to clearly state objectives and pre-defined eligibility criteria for studies (e.g., inclusion and exclusion criteria, etc.);
- Authors have to clearly describe the methods used for locating, selecting, extracting, and synthesizing data;
- The methodology should be accurate and reproducible;
- Authors have to conduct a systematic search that aims at identifying all relevant studies on the topic analyzed;
- Authors have to assess the validity of the findings of the included studies (e.g., risk of bias);
- Authors have to present a systematic analysis with detailed characteristics and findings of the included studies.
Case Reports will be considered for publication only if of particular interest and if accompanied by a review of the literature on the specific topic covered in the manuscript. In particular, we consider for publication Case Reports reporting unusual clinical conditions, unreported diseases, rare side effects of therapy, and so on. The abstract should be no longer than 300 words and should highlight all your key points concisely. It should be structured as follows: BACKGROUND; CASE REPORT or CASE PRESENTATION; CONCLUSIONS. Case Reports have to include the informed consent statement. Permission or written consent should be obtained to draft the manuscript. The consent can be obtained by the patient or parents in case the patient is a minor.
Short Reports and Case Reports will be considered for publication only if of particular interest and accompanied by a short review. The structured abstract must not exceed 300 words.
Abstract Books and Conference Proceedings
Conference proceedings consist of a collection of abstracts and/or posters that were presented at an association’s conference. These articles provide opportunities for researchers to present their research and gain insights from other researchers and colleagues in their field.
European Review for Medical and Pharmacological Sciences considers the publication of Abstract books and/or Conference Proceedings only if of particular interest. Conference proceedings should comprehend abstracts and/or written records of an academic meeting, such as a conference, workshop, congress, symposium, or other professional meeting hosted by an academic or research organization.
Conference abstract books and/or proceedings are published online with an associated DOI. Reprints will be evaluated on request.
All contents of the abstract book will be published in English and must contain:
- The title, authors’ names and affiliations, and a list of keywords.
- The abstract should not exceed 250 words and should be organized as follows: Objectives, Materials or Patients and Methods, Results, and Conclusions.
- Final statements, including conflict of Interest, acknowledgments, informed consent, authors’ contribution, funding, ethics statement, ORCID ID, should be included – when applicable.
- The authors’ index is also mandatory at the end of the text.
Brief Communications are short manuscripts that have important and generally preliminary data on a specific issue. They are considered for publication only if of particular interest.
Editorials are short articles that provide an insight into issues of topical importance to the journal’s target audience or researchers. The articles should provide an expert perspective on a topic of recent interest. This contribution is usually solicited by the Editors. If unsolicited, the authors are advised to contact the Editor-in-Chief (firstname.lastname@example.org) with an outline of the proposed review and CV of the authors.
Letters to the Editor
Letters to the Editor consist of comments on an article previously published on European Review for Medical and Pharmacological Sciences. The inclusion of Letters to the Editor in the journal is at the discretion of the Editor-in-Chief, and they undergo peer-review. All Letters to the Editor will be subsequently sent to the author of the original article, who will have 60 days to provide a Reply to be published alongside the Letter.
Other guidelines have been developed and should be followed for different study designs:
- CONSORT for randomized trials;
- STROBE for observational studies;
- STARD for studies of diagnostic accuracy.
In particular, good sources for reporting guidelines are the EQUATOR Network and the NLM’s Research Reporting Guidelines and Initiatives.
Article length and word count
In most cases, there is no strict limit on word count or number of pages, tables, figures and references. However, the editorial recommendation is that authors write concisely. The main text should be no more than 6,000 words long (not including Abstract, References and Figure legends). Articles should not contain more than 250 references.
Exceptions apply for the main text of Brief Communications (maximum length: 5,000 words with up to 30 references and 2 tables and/or figures), Editorials (maximum length: 10,000 words with up to 30 references and 2 tables and/or figures) and Opinion Papers (maximum length: 10,000 words with up to 30 references and 2 tables and/or figures). Letters are restricted to the discussion of papers already published in the journal, with a maximum of 1,000 words, one table or figure and up to 20 references.